Quantitative pharmacogenetics of nortriptyline: A Novel approach

Clinical Pharmacokinetics

Volumn 40, Issue 11, 2001, Pages 869-877

  Kvist, E E ^a   Al Shurbaji, A ^a   Dahl, M L ^a,b   Nordin, C ^c   Alvan G ^a,d   Stahle L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Medical Product Agency   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; NORTRIPTYLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; NONLINEAR SYSTEM; PHARMACOGENETICS; PRIORITY JOURNAL; STEADY STATE; SWEDEN;

EID: 0035183630     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140110-00005     Document Type: Article

References (34)

1. Plasma levels of monomethylated anti-depressants during treatment with imipramine compounds
2. Genetic control of nortriptyline kinetics in man: A study of relatives of propositi with high plasma concentration
3. Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy
4. E- and Z-10 hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation
5. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects
6. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
7. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequency and evolution
8. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
9. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
10. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
11. Ten percent of north Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
12. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
13. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype
14. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
15. Steady state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
16. Plasma concentraion of nortriptyline and its 10-hydroxymetabolite in depressed patients - Relationship to the debrisoquine hydroxylation ratio
17. Clinical and biochemical effects during treatment of depression with nortriptyline: The role of 10-hydroxynortriptyline
18. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
19. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
20. Hepatic clearance of drugs: I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
21. Hepatic clearance of drugs: II. Experimental evidence for acceptance of the 'well-stirred' model over the 'parallel tube' model using lidocaine in the perfused rat liver in situ preparation
22. Hepatic clearance of drugs: III. Additional experimental evidence supporting the 'well-stirred' model using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparations
23. Modelling first-pass metabolism
24. The availability of orally administered nortriptyline
25. First-pass metabolism of nortriptyline in man
26. First pass hydroxylation of nortriptyline: Concentration of parent drug and major metabolites in plasma
27. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isoenzymes
28. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): Implications for interactions with enzyme-inducing drugs
29. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring
30. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with the nonparametric maximum likelihood method